valsartan has been researched along with D-fructopyranose in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gryciuk, ME; Maciejczyk, M; Mil, KM; Pawlukianiec, C; Zalewska, A; Żendzian-Piotrowska, M; Ładny, JR | 1 |
| Chou, CL; Fang, TC; Li, CH | 1 |
1 review(s) available for valsartan and D-fructopyranose
| Article | Year |
|---|---|
Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and
Topics: Acetylcysteine; Animals; Antioxidants; Captopril; Chloramines; Chromans; Fructose; Glucose; Glycosylation; Humans; Metformin; Oxidation-Reduction; Pyruvaldehyde; Serum Albumin, Bovine; Thioctic Acid; Tosyl Compounds; Valsartan | 2021 |
1 other study(ies) available for valsartan and D-fructopyranose
| Article | Year |
|---|---|
Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.
Topics: Activating Transcription Factor 3; Adiposity; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Fructose; Humans; Hypertension; Lipase; Lipolysis; Monoacylglycerol Lipases; Obesity; Stearoyl-CoA Desaturase; Tetrazoles; Triglycerides; Valsartan | 2022 |